Skip to content Skip to footer
Subscribe Now

INSIGHTS+

Insights+: The US FDA New Drug Approvals in January 2024
Insights+: The US FDA New Drug Approvals in January 2024
Shots:  The US FDA approved 1 NDA in January 2024, leading to treatments for patients and advances in the healthcare industry  In January 2023, Zelsuvmi was approved by the US FDA for the Treatment of Molluscum Contagiosum  PharmaShots has compiled a list of US FDA-approved drugs in the month January 2024  1. Ligand Pharmaceuticals’ Zelsuvmi Receives…
February 8, 2024
Insights+ Key Biosimilars Events of January 2024
Insights+ Key Biosimilars Events of January 2024
Shots:   Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency    Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients    During January, Coherus BioSciences divested its Ophthalmology Franchise that included Cimerli and Glenmark launched…
February 7, 2024
A Complete Account of FDA Approvals in 2023
A Complete Account of FDA Approvals in 2023
Shots:  2023 remained a year of notable approvals by the US FDA. Around 55 drugs were approved, by the US FDA in 2023  PharmaShots, in an enlightening report, brings a summarized analysis of the approved drugs. The most explored section remains Oncology, Neurology, and Hematology   For the complete report with analysis, reach out to us…
February 1, 2024
Know Your Investor (January Edition): RA Capital Management LLC  
Know Your Investor (January Edition): RA Capital Management LLC  
Shots:   New Year, New Us! Our hand-curated “Know Your Investor” reports will now be exploring leading investors of 2023   Founded in 2002, RA Capital forged ahead to become a key investor in life science and healthcare companies. In 2023, RA Capital closed 40 major investments in biopharma companies, devices, manufacturing, service offering firms, and diagnostics  …
January 31, 2024
Top Performing Drug – Perjeta (January Edition)
Top Performing Drug – Perjeta (January Edition)
Shots:   In continuation of our previous series on the Top-Performing Drug of the month, based on 2021 revenue, this month we have selected Perjeta and prepared a curated analysis report for our readers  Perjeta is indicated for the treatment of HER2-positive metastatic breast cancer, neoadjuvant HER2-positive breast cancer, Adjuvant HER2-positive breast cancer PharmaShots presents a concise…
January 30, 2024
New Drug Designations - December 2023
New Drug Designations – December 2023
Shots:  PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, EC, and China’s NMPA. This month’s report includes 6 biological drugs, 10 small molecules, 5 cell and gene therapies, 1 recombinant fusion protein, 1 peptide and 2 devices   Neurocrine Biosciences’ Crinecerfont, focused on the treatment of Congenital Adrenal Hyperplasia…
January 25, 2024
Insights+: EMA Marketing Authorization of New Drugs in December 2023
Insights+: EMA Marketing Authorization of New Drugs in December 2023
Shots:  The EMA approved 3 BLA while 4 New Chemical Entities in December 2023, leading to treatments for patients and advances in the healthcare industry In December 2023, the major highlighted drugs were Jempreli to treat dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer and Zilbrysq for the treatment of Generalized Myasthenia Gravis   PharmaShots has compiled a list of a…
January 23, 2024
Insights+: The US FDA New Drug Approvals in December 2023
Insights+: The US FDA New Drug Approvals in December 2023 
Shots: The US FDA approved 11 NDAs & 2 BLAs in December 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 109 novel products in 2023 In December 2023, the major highlight drugs were Jaypirca (pirtobrutinib) approved for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, and Iwilfin…
January 17, 2024
PharmaShots' Key Highlights of Fourth Quarter 2023
PharmaShots’ Key Highlights of Fourth Quarter 2023
Shots:  The Fourth quarter of 2023 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. Starting with the latest acquisitions, BMS acquired Mirati Therapeutics for ~$5.8B and AbbVie acquired ImmunoGen for $10.1B     The Fourth quarter of the year also showcases multiple clinical trial results from Regeneron’s Two-Year…
January 16, 2024
J.P. Morgan Special: Dealmaker of the Year 2023 (Part 02)
J.P. Morgan Special: Dealmaker of the Year 2023 (Part 02) 
Shots:  In the next installment of Dealmaker 2023, we bring an informative report on the Top M&A based on the Deal Value   The report revolves around Pfizer, which signed 16 collaborations comprising acquisitions, contract services, development & commercialization, license, R&D, and product purchases that have summed to a total of $63.23B   Propelled by the invaluable…
January 15, 2024
Load more